Literature DB >> 8748672

Nitrite, nitrate and cGMP in the cerebrospinal fluid in degenerative neurologic diseases.

M Ikeda1, I Sato, T Yuasa, T Miyatake, S Murota.   

Abstract

To investigate whether nitric oxide (NO) plays a role in degenerative neurologic disease (DND), we measured nitrite, nitrate and cyclic GMP in cerebrospinal fluid (CSF) samples from patients with Parkinson's disease (PD), spinocerebellar ataxia (SCA) and amyotrophic lateral sclerosis (ALS). We found no significant change in CSF nitrite, nitrate or cyclic GMP in patients with any DND compared with control values. These results suggest that NO production is preserved in PD, SCA and ALS.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8748672     DOI： 10.1007/bf01276464

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  25 in total

1.  Cerebellar nitric oxide synthase activity is reduced in nervous and Purkinje cell degeneration mutants but not in climbing fiber-lesioned mice.

Authors:  M Ikeda; I Morita; S Murota; F Sekiguchi; T Yuasa; T Miyatake
Journal:  Neurosci Lett       Date:  1993-06-11       Impact factor: 3.046

2.  Cerebellar injury induces NADPH diaphorase in Purkinje and inferior olivary neurons in the rat.

Authors:  S Chen; G Aston-Jones
Journal:  Exp Neurol       Date:  1994-04       Impact factor: 5.330

3.  Cerebrospinal fluid nitrite/nitrate levels in neurologic diseases.

Authors:  S Milstien; N Sakai; B J Brew; C Krieger; J H Vickers; K Saito; M P Heyes
Journal:  J Neurochem       Date:  1994-09       Impact factor: 5.372

4.  What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study.

Authors:  A J Hughes; Y Ben-Shlomo; S E Daniel; A J Lees
Journal:  Neurology       Date:  1992-06       Impact factor: 9.910

5.  Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures.

Authors:  V L Dawson; T M Dawson; D A Bartley; G R Uhl; S H Snyder
Journal:  J Neurosci       Date:  1993-06       Impact factor: 6.167

Review 6.  A novel neuronal messenger molecule in brain: the free radical, nitric oxide.

Authors:  T M Dawson; V L Dawson; S H Snyder
Journal:  Ann Neurol       Date:  1992-09       Impact factor: 10.422

7.  Relative sparing of nitric oxide synthase-containing neurons in the hippocampal formation in Alzheimer's disease.

Authors:  B T Hyman; K Marzloff; J J Wenniger; T M Dawson; D S Bredt; S H Snyder
Journal:  Ann Neurol       Date:  1992-12       Impact factor: 10.422

8.  Regulation and subcellular location of nitrogen oxide synthases in RAW264.7 macrophages.

Authors:  H H Schmidt; T D Warner; M Nakane; U Förstermann; F Murad
Journal:  Mol Pharmacol       Date:  1992-04       Impact factor: 4.436

9.  Cortical somatostatin, neuropeptide Y, and NADPH diaphorase neurons: normal anatomy and alterations in Alzheimer's disease.

Authors:  N W Kowall; M F Beal
Journal:  Ann Neurol       Date:  1988-02       Impact factor: 10.422

10.  Neurofibrillary tangles in cholinergic pedunculopontine neurons in Alzheimer's disease.

Authors:  E J Mufson; D C Mash; L B Hersh
Journal:  Ann Neurol       Date:  1988-11       Impact factor: 10.422
View more
  7 in total

1.  No changes in cerebrospinal fluid levels of nitrite, nitrate and cyclic GMP with aging. Short communication.

Authors:  K Yamada; K Nishiwaki; K Hattori; K Senzaki; M Nagata; T Komatsu; Y Shimada; T Nabeshima
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 2.  The role of nitric oxide in neurodegeneration. Potential for pharmacological intervention.

Authors:  J A Molina; F J Jiménez-Jiménez; M Ortí-Pareja; J A Navarro
Journal:  Drugs Aging       Date:  1998-04       Impact factor: 3.923

Review 3.  Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.

Authors:  Michy P Kelly
Journal:  Cell Signal       Date:  2017-11-23       Impact factor: 4.315

4.  Levodopa-induced dyskinesias in Parkinson's disease increase cerebrospinal fluid nitric oxide metabolites' levels.

Authors:  Bruno L Santos-Lobato; Mariza Bortolanza; Lucas César Pinheiro; Marcelo E Batalhão; Ângela V Pimentel; Evelin Capellari-Carnio; Elaine A Del-Bel; Vitor Tumas
Journal:  J Neural Transm (Vienna)       Date:  2021-12-23       Impact factor: 3.575

5.  CSF concentrations of cAMP and cGMP are lower in patients with Creutzfeldt-Jakob disease but not Parkinson's disease and amyotrophic lateral sclerosis.

Authors:  Patrick Oeckl; Petra Steinacker; Stefan Lehnert; Sarah Jesse; Hans A Kretzschmar; Albert C Ludolph; Markus Otto; Boris Ferger
Journal:  PLoS One       Date:  2012-03-02       Impact factor: 3.240

Review 6.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

7.  Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression.

Authors:  Raphael Hesse; Ludwig Lausser; Pauline Gummert; Florian Schmid; Anke Wahler; Cathrin Schnack; Katja S Kroker; Markus Otto; Hayrettin Tumani; Hans A Kestler; Holger Rosenbrock; Christine A F von Arnim
Journal:  Alzheimers Res Ther       Date:  2017-03-09       Impact factor: 6.982
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.